IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer

2021 ◽  
Vol 522 ◽  
pp. 32-43
Author(s):  
Heng Liang ◽  
Tianqi Li ◽  
Xin Fang ◽  
Zikang Xing ◽  
Shengnan Zhang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Dual Inhibitor ◽  
Preclinical Efficacy

TGF-β2 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: preclinical efficacy data

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4106-4106 ◽  
Author(s):  
G. Stauder ◽  
A. Bischof ◽  
T. Egger ◽  
M. Hafner ◽  
H. Herrmuth ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Antisense Oligonucleotide ◽  
Efficacy Data ◽  
Preclinical Efficacy

scholarly journals Broad-Spectrum G Protein–Coupled Receptor Antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: A Dual Inhibitor of Growth and Angiogenesis in Pancreatic Cancer

2005 ◽  
Vol 65 (7) ◽  
pp. 2738-2745 ◽  
Author(s):  
Sushovan Guha ◽  
Guido Eibl ◽  
Krisztina Kisfalvi ◽  
Robert S. Fan ◽  
Marie Burdick ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Receptor Antagonist ◽  
G Protein ◽  
Broad Spectrum ◽  
G Protein Coupled Receptor ◽  
Dual Inhibitor ◽  
G Protein Coupled

Abstract 751: Preclinical efficacy of the novel PIM inhibitor, JP_11646, in pancreatic cancer

2014 ◽  
Author(s):  
Yi Ding ◽  
Vun-Sin Lim ◽  
Carmen M. Baldino ◽  
Justin Caserta ◽  
Yvonne Flanders ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
The Novel ◽  
Preclinical Efficacy

Abstract 2935: Preclinical efficacy of the p70S6K/AKT dual inhibitor M2698 in combination with trastuzumab in models of gastric cancer

2018 ◽  
Author(s):  
Shota Fukuoka ◽  
Takashi Kojima ◽  
Yoshikatsu Koga ◽  
Mayumi Yamauchi ◽  
Masahiro Yasunaga ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dual Inhibitor ◽  
Preclinical Efficacy
Sign in / Sign up

Export Citation Format

Share Document